Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FLT3-ITD measurable residual disease from the QuANTUM-First trial.

Blood advances - 10 Feb 2026

Levis Mark J, Erba Harry P, Montesinos Pau, Kim Hee-Je, Vrhovac Radovan, Patkowska Elżbieta, Žák Pavel, Wang Po-Nan, Connolly Rohrbach Jaime E, Chang Ken C N, Liu Li, Mostafa Kamel Yasser, Imadalou Karima, Lesegretain Arnaud, Cortes Jorge, Sekeres Mikkael A, Dombret Hervé, Amadori Sergio, Wang Jianxiang, Schlenk Richard F, Perl Alexander E

Abstract excerpt

ABSTRACT: QuANTUM-First was a randomized trial that demonstrated that the addition of quizartinib, a potent and selective FMS-like tyrosine kinase 3 (FLT3) inhibitor, to induction and consolidation chemotherapy, followed by monotherapy maintenance, improved the survival for patients with newly diagnosed FLT3-internal tandem duplication (FLT3-ITD)-mutated acute myeloid leukemia. We conducted a post hoc analysis of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzothiazoles
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Neoplasm, Residual

Share to Nucleophosmin

Share to Phenylurea Compounds

Share to Protein Kinase Inhibitors

Share to Tandem Repeat Sequences

Source

Open in PubMed Open full text

Identifiers

PMID: 41052406
DOI: 10.1182/bloodadvances.2025016444
PMCID: PMC12905609

Genes

FLT3
NPM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FLT3-ITD measurable residual disease from the QuANTUM-First trial.PMID 41052406Read ↗

QuANTUM-First: Clinical Validation of the LeukoStrat Companion Diagnostic for the Selection of Patients With Acute Myeloid Leukemia Harboring FMS-Like Tyrosine Kinase 3-Internal Tandem Duplications for Treatment With Quizartinib.Semantic proximity Read ↗

Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML.Semantic proximity Read ↗

Quizartinib: a new hope in acute myeloid leukemia, an applied comprehensive review.Semantic proximity Read ↗

<em>FLT3</em>-ITD Measurable Residual Disease in Acute Myeloid Leukemia: Implications for <em>FLT3</em> Inhibitor-Based TherapiesSemantic proximity Read ↗

Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study resultsSemantic proximity Read ↗

Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.Semantic proximity Read ↗

Clonal Dynamics of FLT3-ITD from Diagnosis to Relapse: Ultra-Sensitive Patient-Specific Monitoring by ddPCR.Semantic proximity Read ↗

Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia.Semantic proximity Read ↗

Pre-MEASURE:<i>FLT3</i>-ITD and mutated<i>NPM1</i>measurable residual disease before allogeneic transplant in adults with AML in first remissionSemantic proximity Read ↗

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin.Semantic proximity Read ↗

Deep Sequencing of FLT3-ITD Enables Response Evaluation and Post-Treatment Monitoring in Childhood AML: An Exploratory Study.Semantic proximity Read ↗

Measurable residual disease intervention in AML: a new therapeutic horizon.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.